Ishita Drugs & Industries Limited has announced that its board of directors will meet on Saturday, May 30, 2026. The primary agenda of the meeting is to consider, approve, and take on record the audited financial results of the company for the quarter and year ended March 31, 2026, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Agenda for the Meeting

The board will deliberate on several key matters during the session. Alongside the financial results, the directors are scheduled to consider and approve the Directors' Report, including annexures. This encompasses the Corporate Governance Report and the Management Discussion and Analysis Report. Furthermore, the board will discuss the notice for convening the 33rd Annual General Meeting of the company.

Other Business

The meeting will also address the re-appointment of internal auditors for the upcoming financial year 2026-27. The board is set to take on record the disclosure of interest by directors. Any other matter with the permission of the chair may also be taken up for discussion.

Trading Window Closure

In accordance with the code of conduct for the prevention of insider trading, the trading window for dealing in the securities of the company by designated persons remains closed. The window shut on April 1, 2026, and will remain closed until 48 hours after the announcement of the audited financial results for the quarter and year ended March 31, 2026.

Ishita Drugs & Industries Ltd has notified BSE Limited that SEBI Regulation 32(1) regarding statement of deviation from proceeds is not applicable to the company for the financial year ended 31st March, 2026. The pharmaceutical company confirmed it did not undertake any fund raising activities during this period.

Regulatory Compliance Communication

In a formal communication dated 13th April, 2026, Ishita Drugs & Industries Ltd addressed the Department of Corporate Services at BSE Limited regarding the non-applicability of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company specifically referenced Regulation 32(1), which mandates submission of statements regarding deviation or variation from proceeds of various fund raising mechanisms.

Fund Raising Activities Status

The company explicitly stated that it has not raised any funds through the following mechanisms during FY26:

• Public issue
• Rights issue
• Preferential issue
• Qualified Institutional Placement (QIP)

Due to the absence of any such fund raising activities, the company confirmed that the statement of deviation or variation is not being provided as the regulation is not applicable.

Corporate Authorization

The communication was digitally signed and authorized by Jagdish Agrawal, Managing Director of Ishita Drugs & Industries Ltd, bearing DIN 01031687. The document was submitted to BSE Limited for their records and acknowledgment.

This regulatory filing demonstrates the company's commitment to maintaining transparency and compliance with SEBI listing obligations, even when specific regulations are not applicable to their operations during the reporting period.